Updates in HER2+ Early and Metastatic Breast Cancer - Episode 11
Second-Line Treatment of HER2+ mBC and Recent Data Updates
Maryam Lustberg, MD, MPH introduces the standard of care regimens for the second-line treatment of HER2+ metastatic breast cancer, followed by a discussion of recent data on the ADC trastuzumab deruxtecan (T-DXd).
